SCHEMBL6490879

SCHEMBL6490879

CCC(C)CN(N)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 7/20 0.41
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TSHR P16473 2/20 0.34
GLA P06280 1/20 0.34
POLB P06746 1/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
TAAR1 Q96RJ0 2/20 0.33
LMNA P02545 2/20 0.33
MAOA P21397 1/20 0.33
SLC6A2 P23975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6487412 0.85 AOC3 (0.40) AOC3ALDH1A1KDM4ECYP1A2CYP3A4
SCHEMBL6477129 0.82 AOC3 (0.38) AOC3ALDH1A1KDM4ECYP1A2CYP3A4
SCHEMBL4946334 0.81 AOC3 (0.50) AOC3ALDH1A1POLBAPOBEC3AAPOBEC3G
SCHEMBL6484526 0.81 AOC3 (0.36) AOC3ALDH1A1KDM4ECYP1A2CYP3A4
SCHEMBL8773782 0.77 TRPA1 (0.38) AOC3ALDH1A1KDM4EL3MBTL1POLB
SCHEMBL6487531 0.76 AOC3 (0.66) AOC3TDP1TAAR1MAOAHTR2A
SCHEMBL20035079 0.76 AOC3 (0.35) AOC3ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL6491244 0.73 AOC3 (0.47) AOC3ALDH1A1KDM4EL3MBTL1POLB
SCHEMBL2126003 0.73 ALDH1A1 (0.46) AOC3ALDH1A1KDM4ECYP1A2CYP3A4
SCHEMBL6478164 0.73 ALDH1A1 (0.47) AOC3ALDH1A1KDM4ECYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 US disclosed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 EP disclosed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 US disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP AOC3 1365/4885ALDH1A1 583/4885KDM4E 1796/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP AOC3 1365/4885ALDH1A1 583/4885KDM4E 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.